The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imaging methodology at the molecular, cellular and biosystem level. This is accomplished by facilitating development of novel basic science and clinical research, promoting advances in biotechnology, fostering development of new Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offers customized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancer detection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v) pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescence imaging of live animals and facilitates collaborative microPET research in conjunction with the University at Buffalo (UB).
The aim i s to provide readily available access and training to noninvasive, state-of-the-art in vivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7 days/week. Three general types of MR services are offered: (a) instrumentation and expertise to acquire high resolution (<50 urn2 in-plane spatial and <100 ms temporal) heteronuclear imaging and spectroscopy data, (b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets for probing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnet incorporating Bruker's Avance platform with ParaVision? 4.0 OS, shielded Accustar gradients and digital system electronics. The MR system represents the highest magnetic field strength scanner available within 200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectral fluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also available for fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitative analysis and 3D renderings of digitally acquired data sets are offered as chargeback services. The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSG support is requested, representing 12% of the total operating budget.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Zhao, Zhiguo; Wen, Wanqing; Michailidou, Kyriaki et al. (2016) Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control 27:679-93
Goossens, Maria E; Isa, Fatima; Brinkman, Maree et al. (2016) International pooled study on diet and bladder cancer: the bladder cancer, epidemiology and nutritional determinants (BLEND) study: design and baseline characteristics. Arch Public Health 74:30
Clyde, Merlise A; Palmieri Weber, Rachel; Iversen, Edwin S et al. (2016) Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol 184:579-589
Wilton, John; Kurenova, Elena; Pitzonka, Laura et al. (2016) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. Eur J Drug Metab Pharmacokinet 41:55-67
Sexton, Sandra; Tulowitzki, Ryan; Jones, Craig A et al. (2016) Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model. Clin Exp Nephrol 20:162-8
Shafirstein, Gal; Battoo, Athar; Harris, Kassem et al. (2016) Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 13:265-75
Pharoah, Paul D P; Song, Honglin; Dicks, Ed et al. (2016) PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. J Natl Cancer Inst 108:
Austin, David C; Strand, Douglas W; Love, Harold L et al. (2016) NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Prostate 76:1004-18
Rohrbach, Daniel J; Rigual, Nestor; Arshad, Hassan et al. (2016) Intraoperative optical assessment of photodynamic therapy response of superficial oral squamous cell carcinoma. J Biomed Opt 21:18002
Chinnam, Meenalakshmi; Wang, Xiaoling; Zhang, Xiaojing et al. (2016) Evaluating Effects of Hypomorphic Thoc1 Alleles on Embryonic Development in Rb1 Null Mice. Mol Cell Biol 36:1621-7

Showing the most recent 10 out of 1099 publications